Modality
Radioligand
MOA
Anti-Tau
Target
Cl18.2
Pathway
Fibrosis
EoETTR Amyloidosis
Development Pipeline
Preclinical
Nov 2018
→ Jul 2026
PreclinicalCurrent
NCT05772790
2,415 pts·EoE
2018-11→2026-07·Completed
2,415 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-07-284mo awayInterim· EoE
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
Preclinical
Complet…
Catalysts
Interim
2026-07-28 · 4mo away
EoE
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05772790 | Preclinical | EoE | Completed | 2415 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 |